Literature DB >> 7427900

Preoperative irradiation in carcinoma of the pancreas.

M V Pilepich, H H Miller.   

Abstract

Seventeen patients with carcinoma confined to the pancreas and the peripancreatic area received preoperative radiation therapy in an attempt to increase the resectability rate and to reduce the incidence of recurrence. The tumors were considered either unresectable or of borderline resectability. The radiation dose ranged between 4000--5000 rads, the majority of patients (75%) receiving 4400--4600 rads in 4 1/2--5 weeks. After a period averaging six weeks the patients were reevaluated for surgery. Eleven patients were explored and six underwent radical resection. Two patients remained disease free after five years. Pancreatic resection is feasible following a course of preoperative radiotherapy to a moderately high dose. It is suggested that the response of the primary tumor to radiotherapy be used as a criterion for selecting patients for reexploration and resection.

Entities:  

Mesh:

Year:  1980        PMID: 7427900     DOI: 10.1002/1097-0142(19801101)46:9<1945::aid-cncr2820460908>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Adjuvant and neoadjuvant therapies of pancreatic cancer: a review.

Authors:  J Harris; H Bruckner
Journal:  Int J Pancreatol       Date:  2001

Review 2.  Current and emerging treatments for pancreatic cancer.

Authors:  W F Regine; W J John; M Mohiuddin
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

3.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.

Authors:  Michael D Chuong; Tom J Hayman; Manish R Patel; Mark S Russell; Mokenge P Malafa; Pamela J Hodul; Gregory M Springett; Junsung Choi; Ravi Shridhar; Sarah E Hoffe
Journal:  Gastrointest Cancer Res       Date:  2011-07

5.  Intraoperative electron beam therapy for unresectable cancer of the pancreas.

Authors:  R R Dobelbower; A elTaki; F Bagne; M I Ajlouni; A J Milligan; D G Bronn
Journal:  Int J Pancreatol       Date:  1989-02

6.  Neoadjuvant therapy for pancreatic cancer: an ongoing debate.

Authors:  Suzanne Russo; M Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2016-05-10       Impact factor: 4.409

Review 7.  Preoperative combined modality therapy for pancreatic cancer.

Authors:  T A Rich; D B Evans
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

8.  Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.

Authors:  Ralf Wilkowski; Martin Thoma; Rolf Schauer; Andreas Wagner; Volker Heinemann
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

Review 9.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

10.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Authors:  C G Willett; K Lewandrowski; A L Warshaw; J Efird; C C Compton
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.